Lysophosphatidic Acid and Autotaxin-associated Effects on the Initiation and Progression of Colorectal Cancer
Abstract
:1. Introduction
2. LPA metabolism and signaling
3. Autotaxin
4. LPA1
5. LPA2
6. LPA3
7. LPA4
8. LPA5
9. LPA6
10. Conclusions
Funding
Conflicts of Interest
References
- Arnold, M.; Sierra, M.S.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017, 66, 683–691. [Google Scholar] [CrossRef] [PubMed]
- Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [Google Scholar] [CrossRef]
- Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759–767. [Google Scholar] [CrossRef]
- Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330–337. [CrossRef] [PubMed]
- Huyghe, J.R.; Bien, S.A.; Harrison, T.A.; Kang, H.M.; Chen, S.; Schmit, S.L.; Conti, D.V.; Qu, C.; Jeon, J.; Edlund, C.K.; et al. Discovery of common and rare genetic risk variants for colorectal cancer. Nat. Genet. 2019, 51, 76–87. [Google Scholar] [CrossRef] [PubMed]
- Peterson, L.W.; Artis, D. Intestinal epithelial cells: Regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 2014, 14, 141–153. [Google Scholar] [CrossRef] [PubMed]
- Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to Virchow? Lancet 2001, 357, 539–545. [Google Scholar] [CrossRef]
- Jess, T.; Rungoe, C.; Peyrin-Biroulet, L. Risk of colorectal cancer in patients with ulcerative colitis: A meta-analysis of population-based cohort studies. Clin. Gastroenterol. Hepatol. 2012, 10, 639–645. [Google Scholar] [CrossRef] [PubMed]
- Kappelman, M.D.; Farkas, D.K.; Long, M.D.; Erichsen, R.; Sandler, R.S.; Sorensen, H.T.; Baron, J.A. Risk of cancer in patients with inflammatory bowel diseases: A nationwide population-based cohort study with 30 years of follow-up evaluation. Clin. Gastroenterol. Hepatol. 2014, 12, 265–273.e1. [Google Scholar] [CrossRef]
- Lakatos, P.L.; Lakatos, L. Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World J. Gastroenterol. 2008, 14, 3937–3947. [Google Scholar] [CrossRef] [Green Version]
- Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436–444. [Google Scholar] [CrossRef] [PubMed]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed]
- Ramaswami, R.; Harding, V.; Newsom-Davis, T. Novel cancer therapies: Treatments driven by tumour biology. Postgrad. Med. J. 2013, 89, 652–658. [Google Scholar] [CrossRef] [PubMed]
- Yung, Y.C.; Stoddard, N.C.; Chun, J. LPA receptor signaling: Pharmacology, physiology, and pathophysiology. J. Lipid Res. 2014, 55, 1192–1214. [Google Scholar] [CrossRef] [PubMed]
- Lin, M.E.; Herr, D.R.; Chun, J. Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 2010, 91, 130–138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aoki, J. Mechanisms of lysophosphatidic acid production. Semin. Cell Dev. Biol. 2004, 15, 477–489. [Google Scholar] [CrossRef]
- van Meeteren, L.A.; Ruurs, P.; Stortelers, C.; Bouwman, P.; van Rooijen, M.A.; Pradere, J.P.; Pettit, T.R.; Wakelam, M.J.; Saulnier-Blache, J.S.; Mummery, C.L.; et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 2006, 26, 5015–5022. [Google Scholar] [CrossRef]
- Takeuchi, K.; Reue, K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. Am. J. Physiol. Endocrinol. Metab. 2009, 296, E1195–E1209. [Google Scholar] [CrossRef] [Green Version]
- Brindley, D.N.; Pilquil, C. Lipid phosphate phosphatases and signaling. J. Lipid Res. 2009, 50, S225–S230. [Google Scholar] [CrossRef] [Green Version]
- Benesch, M.G.K.; Tang, X.; Venkatraman, G.; Bekele, R.T.; Brindley, D.N. Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo. J. Biomed. Res. 2016, 30, 272–284. [Google Scholar]
- Choi, J.W.; Herr, D.R.; Noguchi, K.; Yung, Y.C.; Lee, C.W.; Mutoh, T.; Lin, M.E.; Teo, S.T.; Park, K.E.; Mosley, A.N.; et al. LPA receptors: Subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 157–186. [Google Scholar] [CrossRef] [PubMed]
- Houben, A.J.; Moolenaar, W.H. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev. 2011, 30, 557–565. [Google Scholar] [CrossRef] [PubMed]
- Yanagida, K.; Kurikawa, Y.; Shimizu, T.; Ishii, S. Current progress in non-Edg family LPA receptor research. Biochim. Biophys. Acta 2013, 1831, 33–41. [Google Scholar] [CrossRef] [PubMed]
- Chun, J.; Hla, T.; Lynch, K.R.; Spiegel, S.; Moolenaar, W.H. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature. Pharmacol. Rev. 2010, 62, 579–587. [Google Scholar] [CrossRef] [PubMed]
- Oka, S.; Ota, R.; Shima, M.; Yamashita, A.; Sugiura, T. GPR35 is a novel lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 2010, 395, 232–237. [Google Scholar] [CrossRef] [PubMed]
- Tabata, K.I.; Baba, K.; Shiraishi, A.; Ito, M.; Fujita, N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 2007, 363, 861–866. [Google Scholar] [CrossRef]
- Murakami, M.; Shiraishi, A.; Tabata, K.; Fujita, N. Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 2008, 371, 707–712. [Google Scholar] [CrossRef]
- MacKenzie, A.; Lappin, J.; Taylor, D.; Nicklin, S.; Milligan, G. GPR35 as a Novel Therapeutic Target. Front. Endocrinol. 2011, 2, 68. [Google Scholar] [CrossRef] [Green Version]
- Imielinski, M.; Baldassano, R.N.; Griffiths, A.; Russell, R.K.; Annese, V.; Dubinsky, M.; Kugathasan, S.; Bradfield, J.P.; Walters, T.D.; Sleiman, P.; et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat. Genet. 2009, 41, 1335–1340. [Google Scholar] [CrossRef] [Green Version]
- Farooq, S.M.; Hou, Y.; Li, H.; O’Meara, M.; Wang, Y.; Li, C.; Wang, J.-M. Disruption of GPR35 Exacerbates Dextran Sulfate Sodium-Induced Colitis in Mice. Dig. Dis. Sci. 2018, 63, 2910–2922. [Google Scholar] [CrossRef]
- Tsukahara, T.; Hamouda, N.; Utsumi, D.; Matsumoto, K.; Amagase, K.; Kato, S. G protein-coupled receptor 35 contributes to mucosal repair in mice via migration of colonic epithelial cells. Pharmacol. Res. 2017, 123, 27–39. [Google Scholar] [CrossRef] [PubMed]
- Yan, M.; Li, H.; Zhu, M.; Zhao, F.; Zhang, L.; Chen, T.; Jiang, G.; Xie, H.; Cui, Y.; Yao, M.; et al. G Protein-Coupled Receptor 87 (GPR87) Promotes the Growth and Metastasis of CD133+ Cancer Stem-Like Cells in Hepatocellular Carcinoma. PLoS ONE 2013, 8, e61056. [Google Scholar] [CrossRef]
- Wang, L.; Zhou, W.; Zhong, Y.; Huo, Y.; Fan, P.; Zhan, S.; Xiao, J.; Jin, X.; Gou, S.; Yin, T.; et al. Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-κB signaling pathway. Mol. Cancer 2017, 16, 61. [Google Scholar] [CrossRef] [PubMed]
- Hwang, W.L.; Jiang, J.K.; Yang, S.H.; Huang, T.S.; Lan, H.Y.; Teng, H.W.; Yang, C.Y.; Tsai, Y.P.; Lin, C.H.; Wang, H.W.; et al. MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. Nat. Cell Biol. 2014, 16, 268–280. [Google Scholar] [CrossRef] [PubMed]
- Lin, S.; Lee, S.J.; Shim, H.; Chun, J.; Yun, C.C. The Absence of LPA receptor 2 Reduces the Tumorigenesis by ApcMin Mutation in the Intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299, G1128–G1138. [Google Scholar] [CrossRef] [PubMed]
- Lin, S.; Wang, D.; Iyer, S.; Ghaleb, A.M.; Shim, H.; Yang, V.W.; Chun, J.; Yun, C.C. The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology 2009, 136, 1711–1720. [Google Scholar] [CrossRef] [PubMed]
- Goetzl, E.J.; Kong, Y.; Voice, J.K. Cutting edge: Differential constitutive expression of functional receptors for lysophosphatidic acid by human blood lymphocytes. J. Immunol. 2000, 164, 4996–4999. [Google Scholar] [CrossRef] [PubMed]
- Kotarsky, K.; Boketoft, A.; Bristulf, J.; Nilsson, N.E.; Norberg, A.; Hansson, S.; Owman, C.; Sillard, R.; Leeb-Lundberg, L.M.; Olde, B. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther. 2006, 318, 619–628. [Google Scholar] [CrossRef] [PubMed]
- Lundequist, A.; Boyce, J.A. LPA5 Is Abundantly Expressed by Human Mast Cells and Important for Lysophosphatidic Acid Induced MIP-1β Release. PLoS ONE 2011, 6, e18192. [Google Scholar] [CrossRef] [PubMed]
- Panther, E.; Idzko, M.; Corinti, S.; Ferrari, D.; Herouy, Y.; Mockenhaupt, M.; Dichmann, S.; Gebicke-Haerter, P.; Di Virgilio, F.; Girolomoni, G.; et al. The influence of lysophosphatidic acid on the functions of human dendritic cells. J. Immunol. 2002, 169, 4129–4135. [Google Scholar] [CrossRef] [PubMed]
- Chan, L.C.; Peters, W.; Xu, Y.; Chun, J.; Farese, R.V., Jr.; Cases, S. LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA). J. Leukoc. Biol. 2007, 82, 1193–1200. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ishii, S.; Hirane, M.; Fukushima, K.; Tomimatsu, A.; Fukushima, N.; Tsujiuchi, T. Diverse effects of LPA4, LPA5 and LPA6 on the activation of tumor progression in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2015, 461, 59–64. [Google Scholar] [CrossRef] [PubMed]
- Hu, J.; Oda, S.K.; Shotts, K.; Donovan, E.E.; Strauch, P.; Pujanauski, L.M.; Victorino, F.; Al-Shami, A.; Fujiwara, Y.; Tigyi, G.; et al. Lysophosphatidic Acid receptor 5 inhibits B cell antigen receptor signaling and antibody response. J. Immunol. 2014, 193, 85–95. [Google Scholar] [CrossRef] [PubMed]
- Goding, J.W.; Grobben, B.; Slegers, H. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim. Biophys. Acta 2003, 1638, 1–19. [Google Scholar] [CrossRef] [Green Version]
- Aoki, J.; Inoue, A.; Okudaira, S. Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta 2008, 1781, 513–518. [Google Scholar] [CrossRef] [PubMed]
- Tokumura, A.; Majima, E.; Kariya, Y.; Tominaga, K.; Kogure, K.; Yasuda, K.; Fukuzawa, K. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 2002, 277, 39436. [Google Scholar] [CrossRef] [PubMed]
- Hausmann, J.; Perrakis, A.; Moolenaar, W.H. Structure-function relationships of autotaxin, a secreted lysophospholipase D. Adv. Biol. Regul. 2013, 53, 112–117. [Google Scholar] [CrossRef]
- Jansen, S.; Stefan, C.; Creemers, J.W.; Waelkens, E.; Van Eynde, A.; Stalmans, W.; Bollen, M. Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D. J. Cell Sci. 2005, 118, 3081–3089. [Google Scholar] [CrossRef] [Green Version]
- Fulkerson, Z.; Wu, T.; Sunkara, M.; Kooi, C.V.; Morris, A.J.; Smyth, S.S. Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J. Biol. Chem. 2011, 286, 34654–34663. [Google Scholar] [CrossRef]
- Houben, A.J.; van Wijk, X.M.; van Meeteren, L.A.; van Zeijl, L.; van de Westerlo, E.M.; Hausmann, J.; Fish, A.; Perrakis, A.; van Kuppevelt, T.H.; Moolenaar, W.H. The polybasic insertion in autotaxin alpha confers specific binding to heparin and cell surface heparan sulfate proteoglycans. J. Biol. Chem. 2013, 288, 510–519. [Google Scholar] [CrossRef]
- Tomsig, J.L.; Snyder, A.H.; Berdyshev, E.V.; Skobeleva, A.; Mataya, C.; Natarajan, V.; Brindley, D.N.; Lynch, K.R. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem. J. 2009, 419, 611–618. [Google Scholar] [CrossRef] [PubMed]
- Albers, H.M.; Dong, A.; van Meeteren, L.A.; Egan, D.A.; Sunkara, M.; van Tilburg, E.W.; Schuurman, K.; van Tellingen, O.; Morris, A.J.; Smyth, S.S.; et al. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc. Natl. Acad. Sci. USA 2010, 107, 7257–7262. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takara, K.; Eino, D.; Ando, K.; Yasuda, D.; Naito, H.; Tsukada, Y.; Iba, T.; Wakabayashi, T.; Muramatsu, F.; Kidoya, H.; et al. Lysophosphatidic Acid Receptor 4 Activation Augments Drug Delivery in Tumors by Tightening Endothelial Cell-Cell Contact. Cell Rep. 2017, 20, 2072–2086. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yukiura, H.; Kano, K.; Kise, R.; Inoue, A.; Aoki, J. Autotaxin Overexpression Causes Embryonic Lethality and Vascular Defects. PLoS ONE 2015, 10, e0126734. [Google Scholar] [CrossRef] [PubMed]
- Katsifa, A.; Kaffe, E.; Nikolaidou-Katsaridou, N.; Economides, A.N.; Newbigging, S.; McKerlie, C.; Aidinis, V. The Bulk of Autotaxin Activity Is Dispensable for Adult Mouse Life. PLoS ONE 2015, 10, e0143083. [Google Scholar] [CrossRef] [PubMed]
- Seibler, J.; Zevnik, B.; Kuter-Luks, B.; Andreas, S.; Kern, H.; Hennek, T.; Rode, A.; Heimann, C.; Faust, N.; Kauselmann, G.; et al. Rapid generation of inducible mouse mutants. Nucleic Acids Res. 2003, 31, e12. [Google Scholar] [CrossRef] [PubMed]
- Lin, S.; Haque, A.; Raeman, R.; Guo, L.; He, P.; Denning, T.L.; El-Rayes, B.; Moolenaar, W.H.; Yun, C.C. Autotaxin determines colitis severity in mice and is secreted by B cells in the colon. FASEB J. 2019, 33, 3623–3635. [Google Scholar] [CrossRef] [PubMed]
- Round, J.L.; Mazmanian, S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 2009, 9, 313–323. [Google Scholar] [CrossRef]
- Euer, N.; Schwirzke, M.; Evtimova, V.; Burtscher, H.; Jarsch, M.; Tarin, D.; Weidle, U.H. Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. Anticancer Res. 2002, 22, 733–740. [Google Scholar] [PubMed]
- Benesch, M.G.; Ko, Y.M.; Tang, X.; Dewald, J.; Lopez-Campistrous, A.; Zhao, Y.Y.; Lai, R.; Curtis, J.M.; Brindley, D.N.; McMullen, T.P. Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer. Endocr. Relat. Cancer 2015, 22, 593–607. [Google Scholar] [CrossRef] [PubMed]
- Kishi, Y.; Okudaira, S.; Tanaka, M.; Hama, K.; Shida, D.; Kitayama, J.; Yamori, T.; Aoki, J.; Fujimaki, T.; Arai, H. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J. Biol. Chem. 2006, 281, 17492–17500. [Google Scholar] [CrossRef] [PubMed]
- Yang, S.Y.; Lee, J.; Park, C.G.; Kim, S.; Hong, S.Y.; Chung, H.C.; Min, S.K.; Han, J.W.; Lee, H.W.; Lee, H.Y. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin. Exp. Metastasis 2002, 19, 603–608. [Google Scholar] [CrossRef]
- Yang, Y.; Mou, L.-j.; Liu, N.; Tsao, M.-S. Autotaxin Expression in Non-Small-Cell Lung Cancer. Am. J. Respir. Cell Mol. Biol. 1999, 21, 216–222. [Google Scholar] [CrossRef] [PubMed]
- Nakai, Y.; Ikeda, H.; Nakamura, K.; Kume, Y.; Fujishiro, M.; Sasahira, N.; Hirano, K.; Isayama, H.; Tada, M.; Kawabe, T.; et al. Specific increase in serum autotaxin activity in patients with pancreatic cancer. Clin. Biochem. 2011, 44, 576–581. [Google Scholar] [CrossRef] [PubMed]
- Leblanc, R.; Lee, S.C.; David, M.; Bordet, J.C.; Norman, D.D.; Patil, R.; Miller, D.; Sahay, D.; Ribeiro, J.; Clezardin, P.; et al. Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone. Blood 2014. [Google Scholar] [CrossRef] [PubMed]
- David, M.; Wannecq, E.; Descotes, F.; Jansen, S.; Deux, B.; Ribeiro, J.; Serre, C.-M.; Grès, S.; Bendriss-Vermare, N.; Bollen, M.; et al. Cancer Cell Expression of Autotaxin Controls Bone Metastasis Formation in Mouse through Lysophosphatidic Acid-Dependent Activation of Osteoclasts. PLoS ONE 2010, 5, e9741. [Google Scholar] [CrossRef] [PubMed]
- Kazama, S.; Kitayama, J.; Aoki, J.; Mori, K.; Nagawa, H. Immunohistochemical detection of autotaxin (ATX)/lysophospholipase D (lysoPLD) in submucosal invasive colorectal cancer. J. Gastrointest. Cancer 2011, 42, 204–211. [Google Scholar] [CrossRef] [PubMed]
- Prestwich, G.D.; Gajewiak, J.; Zhang, H.; Xu, X.; Yang, G.; Serban, M. Phosphatase-resistant analogues of lysophosphatidic acid: Agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim. Biophys. Acta 2008, 1781, 588–594. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hozumi, H.; Hokari, R.; Kurihara, C.; Narimatsu, K.; Sato, H.; Sato, S.; Ueda, T.; Higashiyama, M.; Okada, Y.; Watanabe, C.; et al. Involvement of autotaxin/lysophospholipase D expression in intestinal vessels in aggravation of intestinal damage through lymphocyte migration. Lab. Invest. 2013, 93, 508–519. [Google Scholar] [CrossRef] [PubMed]
- He, P.; Haque, A.; Lin, S.; Cominelli, F.; Yun, C.C. Inhibition of autotaxin alleviates inflammation and increases the expression of sodium-dependent glucose cotransporter 1 and Na(+)/H(+) exchanger 3 in SAMP1/Fc mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2018, 315, G762–G771. [Google Scholar] [CrossRef] [PubMed]
- Nagler-Anderson, C. Man the barrier! Strategic defences in the intestinal mucosa. Nat. Rev. Immunol. 2001, 1, 59–67. [Google Scholar] [PubMed]
- Kanda, H.; Newton, R.; Klein, R.; Morita, Y.; Gunn, M.D.; Rosen, S.D. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat. Immunol. 2008, 9, 415–423. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nakasaki, T.; Tanaka, T.; Okudaira, S.; Hirosawa, M.; Umemoto, E.; Otani, K.; Jin, S.; Bai, Z.; Hayasaka, H.; Fukui, Y.; et al. Involvement of the Lysophosphatidic Acid-Generating Enzyme Autotaxin in Lymphocyte-Endothelial Cell Interactions. Am. J. Pathol. 2008, 173, 1566–1576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Y.; Chen, Y.C.; Krummel, M.F.; Rosen, S.D. Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells. J. Immunol. 2012, 189, 3914–3924. [Google Scholar] [CrossRef] [PubMed]
- Massironi, S.; Rossi, R.E.; Cavalcoli, F.A.; Della Valle, S.; Fraquelli, M.; Conte, D. Nutritional deficiencies in inflammatory bowel disease: Therapeutic approaches. Clin. Nutr. 2013. [Google Scholar] [CrossRef] [PubMed]
- Wright, E.M. The intestinal Na+/glucose cotransporter. Annu. Rev. Physiol. 1993, 55, 575–589. [Google Scholar] [CrossRef]
- Dusaulcy, R.; Rancoule, C.; Grès, S.; Wanecq, E.; Colom, A.; Guigné, C.; van Meeteren, L.A.; Moolenaar, W.H.; Valet, P.; Saulnier-Blache, J.S. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J. Lipid Res. 2011, 52, 1247–1255. [Google Scholar] [CrossRef] [Green Version]
- Black, K.E.; Berdyshev, E.; Bain, G.; Castelino, F.V.; Shea, B.S.; Probst, C.K.; Fontaine, B.A.; Bronova, I.; Goulet, L.; Lagares, D.; et al. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. FASEB J. 2016, 30, 2435–2450. [Google Scholar] [CrossRef] [Green Version]
- Gesta, S.; Simon, M.-F.; Rey, A.; Sibrac, D.; Girard, A.; Lafontan, M.; Valet, P.; Saulnier-Blache, J.S. Secretion of a lysophospholipase D activity by adipocytes: Involvement in lysophosphatidic acid synthesis. J. Lipid Res. 2002, 43, 904–910. [Google Scholar]
- Rancoule, C.; Dusaulcy, R.; Treguer, K.; Gres, S.; Guigne, C.; Quilliot, D.; Valet, P.; Saulnier-Blache, J.S. Depot-specific regulation of autotaxin with obesity in human adipose tissue. J. Physiol. Biochem. 2012, 68, 635–644. [Google Scholar] [CrossRef]
- Benesch, M.G.K.; Tang, X.; Dewald, J.; Dong, W.-F.; Mackey, J.R.; Hemmings, D.G.; McMullen, T.P.W.; Brindley, D.N. Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression. FASEB J. 2015, 29, 3990–4000. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Volden, P.A.; Skor, M.N.; Johnson, M.B.; Singh, P.; Patel, F.N.; McClintock, M.K.; Brady, M.J.; Conzen, S.D. Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor–Negative Mammary Epithelial Cell Proliferation. Cancer Prev. Res. 2016, 9, 367–378. [Google Scholar] [CrossRef] [PubMed]
- Navab, M.; Hough, G.; Buga, G.M.; Su, F.; Wagner, A.C.; Meriwether, D.; Chattopadhyay, A.; Gao, F.; Grijalva, V.; Danciger, J.S.; et al. Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J. Lipid Res. 2013, 54, 3403–3418. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brandon, J.A.; Kraemer, M.; Vandra, J.; Halder, S.; Ubele, M.; Morris, A.J.; Smyth, S.S. Adipose-derived autotaxin regulates inflammation and steatosis associated with diet-induced obesity. PLoS ONE 2019, 14, e0208099. [Google Scholar] [CrossRef] [PubMed]
- Vidot, S.; Witham, J.; Agarwal, R.; Greenhough, S.; Bamrah, H.S.; Tigyi, G.J.; Kaye, S.B.; Richardson, A. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell. Signal. 2010, 22, 926–935. [Google Scholar] [CrossRef]
- Quinn, L.A.; Moore, G.E.; Morgan, R.T.; Woods, L.K. Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. Cancer Res. 1979, 39, 4914–4924. [Google Scholar]
- Bolier, R.; Tolenaars, D.; Kremer, A.E.; Saris, J.; Pares, A.; Verheij, J.; Bosma, P.J.; Beuers, U.; Oude Elferink, R.P.J. Enteroendocrine cells are a potential source of serum autotaxin in men. Biochim. Biophys. Acta 2016, 1862, 696–704. [Google Scholar] [CrossRef]
- Crosnier, C.; Stamataki, D.; Lewis, J. Organizing cell renewal in the intestine: Stem cells, signals and combinatorial control. Nat. Rev. Genet. 2006, 7, 349–359. [Google Scholar] [CrossRef]
- Lee, S.J.; Leoni, G.; Neumann, P.A.; Chun, J.; Nusrat, A.; Yun, C.C. Distinct phospholipase C-beta isozymes mediate lysophosphatidic acid receptor 1 effects on intestinal epithelial homeostasis and wound closure. Mol. Cell. Biol. 2013, 33, 2016–2028. [Google Scholar] [CrossRef]
- Ridley, A.J.; Schwartz, M.A.; Burridge, K.; Firtel, R.A.; Ginsberg, M.H.; Borisy, G.; Parsons, J.T.; Horwitz, A.R. Cell migration: Integrating signals from front to back. Science 2003, 302, 1704–1709. [Google Scholar] [CrossRef]
- Mills, G.B.; Moolenaar, W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 2003, 3, 582–591. [Google Scholar] [CrossRef] [PubMed]
- Hines, O.J.; Ryder, N.; Chu, J.; McFadden, D. Lysophosphatidic Acid Stimulates Intestinal Restitution via Cytoskeletal Activation and Remodeling. J. Surg. Res. 2000, 92, 23–28. [Google Scholar] [CrossRef] [PubMed]
- Cetin, S.; Ford, H.R.; Sysko, L.R.; Agarwal, C.; Wang, J.; Neal, M.D.; Baty, C.; Apodaca, G.; Hackam, D.J. Endotoxin inhibits intestinal epithelial restitution through activation of Rho-GTPase and increased focal adhesions. J. Biol. Chem. 2004, 279, 24592–24600. [Google Scholar] [CrossRef] [PubMed]
- Ishii, I.; Fukushima, N.; Ye, X.; Chun, J. Lysophospholipid receptors: Signaling and biology. Annu. Rev. Biochem. 2004, 73, 321–354. [Google Scholar] [CrossRef] [PubMed]
- Sturm, A.; Sudermann, T.; Schulte, K.M.; Goebell, H.; Dignass, A.U. Modulation of intestinal epithelial wound healing in vitro and in vivo by lysophosphatidic acid. Gastroenterology 1999, 117, 368–377. [Google Scholar] [CrossRef] [PubMed]
- Okayasu, I.; Hatakeyama, S.; Yamada, M.; Ohkusa, T.; Inagaki, Y.; Nakaya, R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98, 694–702. [Google Scholar] [CrossRef]
- Ohta, H.; Sato, K.; Murata, N.; Damirin, A.; Malchinkhuu, E.; Kon, J.; Kimura, T.; Tobo, M.; Yamazaki, Y.; Watanabe, T.; et al. Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors. Mol. Pharmacol. 2003, 64, 994–1005. [Google Scholar] [CrossRef]
- Tanaka, T.; Kassai, A.; Ohmoto, M.; Morito, K.; Kashiwada, Y.; Takaishi, Y.; Urikura, M.; Morishige, J.; Satouchi, K.; Tokumura, A. Quantification of phosphatidic acid in foodstuffs using a thin-layer-chromatography-imaging technique. J. Agric. Food Chem. 2012, 60, 4156–4161. [Google Scholar] [CrossRef]
- Lee, B.H.; Choi, S.H.; Kim, H.J.; Jung, S.W.; Kim, H.K.; Nah, S.Y. Plant Lysophosphatidic Acids: A Rich Source for Bioactive Lysophosphatidic Acids and Their Pharmacological Applications. Biol. Pharm. Bull. 2016, 39, 156–162. [Google Scholar] [CrossRef]
- Nakane, S.; Tokumura, A.; Waku, K.; Sugiura, T. Hen egg yolk and white contain high amounts of lysophosphatidic acids, growth factor-like lipids: Distinct molecular species compositions. Lipids 2001, 36, 413–419. [Google Scholar] [CrossRef]
- Tanaka, T.; Horiuchi, G.; Matsuoka, M.; Hirano, K.; Tokumura, A.; Koike, T.; Satouchi, K. Formation of lysophosphatidic acid, a wound-healing lipid, during digestion of cabbage leaves. Biosci. Biotechnol. Biochem. 2009, 73, 1293–1300. [Google Scholar] [CrossRef] [PubMed]
- Adachi, M.; Horiuchi, G.; Ikematsu, N.; Tanaka, T.; Terao, J.; Satouchi, K.; Tokumura, A. Intragastrically administered lysophosphatidic acids protect against gastric ulcer in rats under water-immersion restraint stress. Dig. Dis. Sci. 2011, 56, 2252–2261. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, T.; Morito, K.; Kinoshita, M.; Ohmoto, M.; Urikura, M.; Satouchi, K.; Tokumura, A. Orally administered phosphatidic acids and lysophosphatidic acids ameliorate aspirin-induced stomach mucosal injury in mice. Dig. Dis. Sci. 2013, 58, 950–958. [Google Scholar] [CrossRef] [PubMed]
- Afroz, S.; Yagi, A.; Fujikawa, K.; Rahman, M.M.; Morito, K.; Fukuta, T.; Watanabe, S.; Kiyokage, E.; Toida, K.; Shimizu, T.; et al. Lysophosphatidic acid in medicinal herbs enhances prostaglandin E2 and protects against indomethacin-induced gastric cell damage in vivo and in vitro. Prostaglandins Other Lipid Mediat. 2018, 135, 36–44. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.-J.; Kim, J.Y.; Lee, B.-H.; Choi, S.-H.; Rhim, H.; Kim, H.-C.; Ahn, S.-Y.; Jeong, S.-W.; Jang, M.; Cho, I.-H.; et al. Gintonin, an exogenous ginseng-derived LPA receptor ligand, promotes corneal wound healing. J. Vet. Sci. 2016. [Google Scholar] [CrossRef] [PubMed]
- Tsutsumi, T.; Inoue, M.; Okamoto, Y.; Ishihara, A.; Tokumura, A. Daily Intake of High-Fat Diet with Lysophosphatidic Acid-Rich Soybean Phospholipids Augments Colon Tumorigenesis in Kyoto Apc Delta Rats. Dig. Dis. Sci. 2017, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Lin, S.; Han, Y.; Jenkin, K.; Lee, S.J.; Sasaki, M.; Klapproth, J.M.; He, P.; Yun, C.C. Lysophosphatidic Acid Receptor 1 Is Important for Intestinal Epithelial Barrier Function and Susceptibility to Colitis. Am. J. Pathol. 2018, 188, 353–366. [Google Scholar] [CrossRef] [PubMed]
- Hollander, D.; Vadheim, C.M.; Brettholz, E.; Petersen, G.M.; Delahunty, T.; Rotter, J.I. Increased intestinal permeability in patients with Crohn’s disease and their relatives. A possible etiologic factor. Ann. Intern. Med. 1986, 105, 883–885. [Google Scholar] [CrossRef] [PubMed]
- Khor, B.; Gardet, A.; Xavier, R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474, 307–317. [Google Scholar] [CrossRef] [Green Version]
- Bischoff, S.C.; Barbara, G.; Buurman, W.; Ockhuizen, T.; Schulzke, J.-D.; Serino, M.; Tilg, H.; Watson, A.; Wells, J.M. Intestinal permeability—A new target for disease prevention and therapy. BMC Gastroenterol. 2014, 14, 189. [Google Scholar] [CrossRef]
- Yu, S.; Murph, M.M.; Lu, Y.; Liu, S.; Hall, H.S.; Liu, J.; Stephens, C.; Fang, X.; Mills, G.B. Lysophosphatidic Acid Receptors Determine Tumorigenicity and Aggressiveness of Ovarian Cancer Cells. J. Natl. Cancer Inst. 2008, 100, 1630–1642. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, M.; Towers, L.N.; O’Connor, K.L. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am. J. Physiol. Cell Physiol. 2007, 292, C1927–C1933. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guo, R.; Kasbohm, E.A.; Arora, P.; Sample, C.J.; Baban, B.; Sud, N.; Sivashanmugam, P.; Moniri, N.H.; Daaka, Y. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 2006, 147, 4883–4892. [Google Scholar] [CrossRef] [PubMed]
- Kataoka, M.; Ishibashi, K.; Kumagai, S.; Yanagida, T.; Aikawa, K.; Chiba, H.; Kojima, Y. Expression and Function of LPA1 in Bladder Cancer. J. Urol. 2015, 194, 238–244. [Google Scholar] [CrossRef] [PubMed]
- Obo, Y.; Yamada, T.; Furukawa, M.; Hotta, M.; Honoki, K.; Fukushima, N.; Tsujiuchi, T. Frequent mutations of lysophosphatidic acid receptor-1 gene in rat liver tumors. Mutat. Res. 2009, 660, 47–50. [Google Scholar] [CrossRef] [PubMed]
- Magkrioti, C.; Oikonomou, N.; Kaffe, E.; Mouratis, M.A.; Xylourgidis, N.; Barbayianni, I.; Megadoukas, P.; Harokopos, V.; Valavanis, C.; Chun, J.; et al. The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis. Cancer Res. 2018, 78, 3634–3644. [Google Scholar] [CrossRef]
- Shida, D.; Watanabe, T.; Aoki, J.; Hama, K.; Kitayama, J.; Sonoda, H.; Kishi, Y.; Yamaguchi, H.; Sasaki, S.; Sako, A.; et al. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab. Invest. 2004, 84, 1352–1362. [Google Scholar] [CrossRef] [Green Version]
- Shida, D.; Kitayama, J.; Yamaguchi, H.; Okaji, Y.; Tsuno, N.H.; Watanabe, T.; Takuwa, Y.; Nagawa, H. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 2003, 63, 1706–1711. [Google Scholar]
- Yun, C.C.; Sun, H.; Wang, D.; Rusovici, R.; Castleberry, A.; Hall, R.A.; Shim, H. LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am. J. Physiol. 2005, 289, C2–C11. [Google Scholar] [CrossRef]
- Shida, D.; Kitayama, J.; Yamaguchi, H.; Hama, K.; Aoki, J.; Arai, H.; Yamashita, H.; Mori, K.; Sako, A.; Konishi, T.; et al. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp. Cell Res. 2004, 301, 168–178. [Google Scholar] [CrossRef]
- Shin, K.J.; Kim, Y.L.; Lee, S.; Kim, D.K.; Ahn, C.; Chung, J.; Seong, J.Y.; Hwang, J.I. Lysophosphatidic acid signaling through LPA receptor subtype 1 induces colony scattering of gastrointestinal cancer cells. J. Cancer Res. Clin. Oncol. 2009, 135, 45–52. [Google Scholar] [CrossRef] [PubMed]
- Sahay, D.; Leblanc, R.; Grunewald, T.G.; Ambatipudi, S.; Ribeiro, J.; Clezardin, P.; Peyruchaud, O. The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget 2015, 6, 20604–20620. [Google Scholar] [CrossRef] [PubMed]
- Komachi, M.; Sato, K.; Tobo, M.; Mogi, C.; Yamada, T.; Ohta, H.; Tomura, H.; Kimura, T.; Im, D.S.; Yanagida, K.; et al. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo. Cancer Sci. 2012, 103, 1099–1104. [Google Scholar] [CrossRef] [PubMed]
- David, M.; Ribeiro, J.; Descotes, F.; Serre, C.M.; Barbier, M.; Murone, M.; Clezardin, P.; Peyruchaud, O. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int. J. Oncol. 2012, 40, 1133–1141. [Google Scholar] [CrossRef]
- Lee, S.C.; Fujiwara, Y.; Liu, J.; Yue, J.; Shimizu, Y.; Norman, D.D.; Wang, Y.; Tsukahara, R.; Szabo, E.; Patil, R.; et al. Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis. Mol. Cancer Res. MCR 2015, 13, 174–185. [Google Scholar] [CrossRef] [PubMed]
- Yang, M.; Zhong, W.W.; Srivastava, N.; Slavin, A.; Yang, J.; Hoey, T.; An, S. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc. Natl. Acad. Sci. USA 2005, 102, 6027–6032. [Google Scholar] [CrossRef]
- Venkatraman, G.; Benesch, M.G.; Tang, X.; Dewald, J.; McMullen, T.P.; Brindley, D.N. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: Implications for cancer treatment. FASEB J. 2014. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, K.; Fukushima, K.; Otagaki, S.; Ishimoto, K.; Minami, K.; Fukushima, N.; Honoki, K.; Tsujiuchi, T. Effects of LPA1 and LPA6 on the regulation of colony formation activity in colon cancer cells treated with anticancer drugs. J. Recept. Signal. Transduct. Res. 2018, 38, 71–75. [Google Scholar] [CrossRef]
- Fukushima, K.; Takahashi, K.; Yamasaki, E.; Onishi, Y.; Fukushima, N.; Honoki, K.; Tsujiuchi, T. Lysophosphatidic acid signaling via LPA1 and LPA3 regulates cellular functions during tumor progression in pancreatic cancer cells. Exp. Cell Res. 2017. [Google Scholar] [CrossRef]
- Yamada, T.; Ohoka, Y.; Kogo, M.; Inagaki, S. Physical and Functional Interactions of the Lysophosphatidic Acid Receptors with PDZ Domain-containing Rho Guanine Nucleotide Exchange Factors (RhoGEFs). J. Biol. Chem. 2005, 280, 19358–19363. [Google Scholar] [CrossRef] [Green Version]
- Varsano, T.; Taupin, V.; Guo, L.; Baterina, O.Y., Jr.; Farquhar, M.G. The PDZ Protein GIPC Regulates Trafficking of the LPA1 Receptor from APPL Signaling Endosomes and Attenuates the Cell’s Response to LPA. PLoS ONE 2012, 7, e49227. [Google Scholar] [CrossRef]
- Shano, S.; Hatanaka, K.; Ninose, S.; Moriyama, R.; Tsujiuchi, T.; Fukushima, N. A lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation. Biochim. Biophys. Acta 2008, 1783, 748–759. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goetzl, E.J.; Dolezalova, H.; Kong, Y.; Hu, Y.-L.; Jaffe, R.B.; Kalli, K.R.; Conover, C.A. Distinctive Expression and Functions of the Type 4 Endothelial Differentiation Gene-encoded G Protein-coupled Receptor for Lysophosphatidic Acid in Ovarian Cancer. Cancer Res. 1999, 59, 5370–5375. [Google Scholar] [PubMed]
- Fang, X.; Gaudette, D.; Furui, T.; Mao, M.; Estrella, V.; Eder, A.; Pustilnik, T.; Sasagawa, T.; Lapushin, R.; Yu, S.; et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann. N. Y. Acad. Sci. 2000, 905, 188–208. [Google Scholar] [CrossRef] [PubMed]
- Schulte, K.M.; Beyer, A.; Kohrer, K.; Oberhauser, S.; Roher, H.D. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: Over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int. J. Cancer 2001, 92, 249–256. [Google Scholar] [CrossRef]
- Kitayama, J.; Shida, D.; Sako, A.; Ishikawa, M.; Hama, K.; Aoki, J.; Arai, H.; Nagawa, H. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. BCR 2004, 6, R640–R646. [Google Scholar] [CrossRef] [PubMed]
- Enooku, K.; Uranbileg, B.; Ikeda, H.; Kurano, M.; Sato, M.; Kudo, H.; Maki, H.; Koike, K.; Hasegawa, K.; Kokudo, N.; et al. Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels. PLoS ONE 2016, 11, e0161825. [Google Scholar] [CrossRef] [PubMed]
- Zhang, G.; Cheng, Y.; Zhang, Q.; Li, X.; Zhou, J.; Wang, J.; Wei, L. ATXLPA axis facilitates estrogeninduced endometrial cancer cell proliferation via MAPK/ERK signaling pathway. Mol. Med. Rep. 2018, 17, 4245–4252. [Google Scholar]
- Yoshida, M.; He, P.; Yun, C.C. Transgenic Expression of Human Lysophosphatidic Acid Receptor LPA2 in Mouse Intestinal Epithelial Cells Induces Intestinal Dysplasia. PLoS ONE 2016, 11, e0154527. [Google Scholar] [CrossRef]
- Zhang, H.; Bialkowska, A.; Rusovici, R.; Chanchevalap, S.; Shim, H.; Katz, J.P.; Yang, V.W.; Yun, C.C. Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5. J. Biol. Chem. 2007, 282, 15541–15549. [Google Scholar] [CrossRef]
- Yang, D.; Yang, W.; Zhang, Q.; Hu, Y.; Bao, L.; Damirin, A. Migration of gastric cancer cells in response to lysophosphatidic acid is mediated by LPA receptor 2. Oncol. Lett. 2013, 5, 1048–1052. [Google Scholar] [CrossRef] [PubMed]
- Morin, P.J.; Kinzler, K.W.; Sparks, A.B. beta-Catenin Mutations: Insights into the APC Pathway and the Power of Genetics. Cancer Res. 2016, 76, 5587–5589. [Google Scholar] [CrossRef] [PubMed]
- Fang, X.; Yu, S.; Tanyi, J.L.; Lu, Y.; Woodgett, J.R.; Mills, G.B. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol. Cell. Biol. 2002, 22, 2099–2110. [Google Scholar] [CrossRef] [PubMed]
- Bienz, M.; Clevers, H. Linking colorectal cancer to Wnt signaling. Cell 2000, 103, 311–320. [Google Scholar] [CrossRef]
- Guo, L.; He, P.; No, Y.R.; Yun, C.C. Kruppel-like factor 5 incorporates into the beta-catenin/TCF complex in response to LPA in colon cancer cells. Cell. Signal. 2015, 27, 961–968. [Google Scholar] [CrossRef]
- McConnell, B.B.; Yang, V.W. Mammalian Kruppel-like factors in health and diseases. Physiol. Rev. 2010, 90, 1337–1381. [Google Scholar] [CrossRef]
- Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721–732. [Google Scholar] [CrossRef]
- Schofield, C.J.; Ratcliffe, P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5, 343–354. [Google Scholar] [CrossRef]
- Patten, D.A.; Lafleur, V.N.; Robitaille, G.A.; Chan, D.A.; Giaccia, A.J.; Richard, D.E. Hypoxia-inducible factor-1 activation in nonhypoxic conditions: The essential role of mitochondrial-derived reactive oxygen species. Mol. Biol. Cell 2010, 21, 3247–3257. [Google Scholar] [CrossRef]
- Lee, J.; Park, S.Y.; Lee, E.K.; Park, C.G.; Chung, H.C.; Rha, S.Y.; Kim, Y.K.; Bae, G.U.; Kim, B.K.; Han, J.W.; et al. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin. Cancer Res. 2006, 12, 6351–6358. [Google Scholar] [CrossRef]
- Lee, S.J.; No, Y.R.; Dang, D.T.; Dang, L.H.; Yang, V.W.; Shim, H.; Yun, C.C. Regulation of hypoxia-inducible factor 1alpha (HIF-1alpha) by lysophosphatidic acid is dependent on interplay between p53 and Kruppel-like factor 5. J. Biol. Chem. 2013, 288, 25244–25253. [Google Scholar] [CrossRef] [PubMed]
- Winner, M.; Koong, A.C.; Rendon, B.E.; Zundel, W.; Mitchell, R.A. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res. 2007, 67, 186–193. [Google Scholar] [CrossRef] [PubMed]
- Sun, B.; Nishihira, J.; Yoshiki, T.; Kondo, M.; Sato, Y.; Sasaki, F.; Todo, S. Macrophage Migration Inhibitory Factor Promotes Tumor Invasion and Metastasis via the Rho-Dependent Pathway. Clin. Cancer Res. 2005, 11, 1050–1058. [Google Scholar] [PubMed]
- No, Y.R.; Lee, S.-J.; Kumar, A.; Yun, C.C. HIF1α-Induced by Lysophosphatidic Acid Is Stabilized via Interaction with MIF and CSN5. PLoS ONE 2015, 10, e0137513. [Google Scholar] [CrossRef] [PubMed]
- Lee, S.J.; Ritter, S.L.; Zhang, H.; Shim, H.; Hall, R.A.; Yun, C.C. MAGI-3 competes with NHERF-2 to negatively regulate LPA2 receptor signaling in colon cancer cells. Gastroenterology 2011, 140, 924–934. [Google Scholar] [CrossRef]
- Zhang, H.; Wang, D.; Sun, H.; Hall, R.A.; Yun, C.C. MAGI-3 regulates LPA-induced activation of Erk and RhoA. Cell. Signal. 2007, 19, 261–268. [Google Scholar] [CrossRef] [Green Version]
- Xu, J.; Lai, Y.-J.; Lin, W.-C.; Lin, F.-T. TRIP6 Enhances Lysophosphatidic Acid-induced Cell Migration by Interacting with the Lysophosphatidic Acid 2 Receptor. J. Biol. Chem. 2004, 279, 10459–10468. [Google Scholar] [CrossRef] [Green Version]
- Lin, F.T.; Lai, Y.J.; Makarova, N.; Tigyi, G.; Lin, W.C. The lysophosphatidic acid 2 receptor mediates down-regulation of Siva-1 to promote cell survival. J. Biol. Chem. 2007, 282, 37759–37769. [Google Scholar] [CrossRef]
- Oh, Y.S.; Jo, N.W.; Choi, J.W.; Kim, H.S.; Seo, S.W.; Kang, K.O.; Hwang, J.I.; Heo, K.; Kim, S.H.; Kim, Y.H.; et al. NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation. Mol. Cell. Biol. 2004, 24, 5069–5079. [Google Scholar] [CrossRef]
- Lai, Y.-J.; Chen, C.-S.; Lin, W.-C.; Lin, F.-T. c-Src-Mediated Phosphorylation of TRIP6 Regulates Its Function in Lysophosphatidic Acid-Induced Cell Migration. Mol. Cell. Biol. 2005, 25, 5859–5868. [Google Scholar] [CrossRef] [Green Version]
- An, S.; Bleu, T.; Hallmark, O.G.; Goetzl, E.J. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 1998, 273, 7906–7910. [Google Scholar] [CrossRef] [PubMed]
- Contos, J.J.; Chun, J. Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA. Genomics 2000, 64, 155–169. [Google Scholar] [CrossRef] [PubMed]
- Deng, W.; Balazs, L.; Wang, D.A.; Van Middlesworth, L.; Tigyi, G.; Johnson, L.R. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology 2002, 123, 206–216. [Google Scholar] [CrossRef] [PubMed]
- Deng, W.; Wang, D.A.; Gosmanova, E.; Johnson, L.R.; Tigyi, G. LPA protects intestinal epithelial cells from apoptosis by inhibiting the mitochondrial pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 284, G821–G829. [Google Scholar] [CrossRef] [PubMed]
- E, S.; Lai, Y.J.; Tsukahara, R.; Chen, C.S.; Fujiwara, Y.; Yue, J.; Yu, J.H.; Guo, H.; Kihara, A.; Tigyi, G.; et al. Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect. J. Biol. Chem. 2009, 284, 14558–14571. [Google Scholar] [CrossRef] [PubMed]
- Rusovici, R.; Ghaleb, A.; Shim, H.; Yang, V.W.; Yun, C.C. Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. Biochim. Biophys. Acta 2007, 1770, 1194–1203. [Google Scholar] [CrossRef] [Green Version]
- Deng, W.; E, S.; Tsukahara, R.; Valentine, W.J.; Durgam, G.; Gududuru, V.; Balazs, L.; Manickam, V.; Arsura, M.; Vanmiddlesworth, L.; et al. The Lysophosphatidic Acid Type 2 Receptor Is Required for Protection Against Radiation-Induced Intestinal Injury. Gastroenterology 2007, 132, 1834–1851. [Google Scholar] [CrossRef] [Green Version]
- Tigyi, G.J.; Johnson, L.R.; Lee, S.C.; Norman, D.D.; Szabo, E.; Balogh, A.; Thompson, K.; Boler, A.L.; McCool, S.W. Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential. J. Lipid Res. 2019. [Google Scholar] [CrossRef]
- Fukui, R.; Tanabe, E.; Kitayoshi, M.; Yoshikawa, K.; Fukushima, N.; Tsujiuchi, T. Negative regulation of cell motile and invasive activities by lysophosphatidic acid receptor-3 in colon cancer HCT116 cells. Tumour Biol. 2012, 33, 1899–1905. [Google Scholar] [CrossRef]
- Kato, K.; Yoshikawa, K.; Tanabe, E.; Kitayoshi, M.; Fukui, R.; Fukushima, N.; Tsujiuchi, T. Opposite roles of LPA1 and LPA3 on cell motile and invasive activities of pancreatic cancer cells. Tumour Biol. 2012, 33, 1739–1744. [Google Scholar] [CrossRef]
- Sun, K.; Cai, H.; Duan, X.; Yang, Y.; Li, M.; Qu, J.; Zhang, X.; Wang, J. Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers. Clin. Exp. Med. 2015, 15, 371–380. [Google Scholar] [CrossRef] [PubMed]
- Koehne, C.H.; Dubois, R.N. COX-2 inhibition and colorectal cancer. Semin. Oncol. 2004, 31, 12–21. [Google Scholar] [CrossRef] [PubMed]
- Ye, X.; Hama, K.; Contos, J.J.A.; Anliker, B.; Inoue, A.; Skinner, M.K.; Suzuki, H.; Amano, T.; Kennedy, G.; Arai, H.; et al. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 2005, 435, 104–108. [Google Scholar] [CrossRef] [PubMed]
- Noguchi, K.; Ishii, S.; Shimizu, T. Identification of p2y9/GPR23 as a Novel G Protein-coupled Receptor for Lysophosphatidic Acid, Structurally Distant from the Edg Family. J. Biol. Chem. 2003, 278, 25600–25606. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, Z.; Cheng, C.T.; Zhang, H.; Subler, M.A.; Wu, J.; Mukherjee, A.; Windle, J.J.; Chen, C.K.; Fang, X. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol. Biol. Cell 2008, 19, 5435–5445. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, K.; Fukushima, K.; Onishi, Y.; Inui, K.; Node, Y.; Fukushima, N.; Honoki, K.; Tsujiuchi, T. Lysophosphatidic acid (LPA) signaling via LPA4 and LPA6 negatively regulates cell motile activities of colon cancer cells. Biochem. Biophys. Res. Commun. 2017, 483, 652–657. [Google Scholar] [CrossRef] [PubMed]
- Harper, K.; Arsenault, D.; Boulay-Jean, S.; Lauzier, A.; Lucien, F.; Dubois, C.M. Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: Participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation. Cancer Res. 2010, 70, 4634–4643. [Google Scholar] [CrossRef] [PubMed]
- Sumida, H.; Noguchi, K.; Kihara, Y.; Abe, M.; Yanagida, K.; Hamano, F.; Sato, S.; Tamaki, K.; Morishita, Y.; Kano, M.R.; et al. LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood 2010, 116, 5060–5070. [Google Scholar] [CrossRef] [PubMed]
- Eino, D.; Tsukada, Y.; Naito, H.; Kanemura, Y.; Iba, T.; Wakabayashi, T.; Muramatsu, F.; Kidoya, H.; Arita, H.; Kagawa, N.; et al. LPA4-Mediated Vascular Network Formation Increases the Efficacy of Anti-PD-1 Therapy against Brain Tumors. Cancer Res. 2018, 78, 6607–6620. [Google Scholar] [CrossRef]
- Lee, C.W.; Rivera, R.; Gardell, S.; Dubin, A.E.; Chun, J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 2006, 281, 23589–23597. [Google Scholar] [CrossRef]
- Lin, S.; Yeruva, S.; He, P.; Singh, A.K.; Zhang, H.; Chen, M.; Lamprecht, G.; de Jonge, H.R.; Tse, M.; Donowitz, M.; et al. Lysophosphatidic acid stimulates the intestinal brush border Na+/H+ exchanger 3 and fluid absorption via LPA5 and NHERF2. Gastroenterology 2010, 138, 649–658. [Google Scholar] [CrossRef] [PubMed]
- Jenkin, K.A.; He, P.; Yun, C.C. Expression of lysophosphatidic acid receptor 5 is necessary for the regulation of intestinal Na(+)/H(+) exchanger 3 by lysophosphatidic acid in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 2018, 315, G433–G442. [Google Scholar] [CrossRef]
- Gurney, M.A.; Laubitz, D.; Ghishan, F.K.; Kiela, P.R. Pathophysiology of Intestinal Na(+)/H(+) exchange. Cell. Mol. Gastroenterol. Hepatol. 2017, 3, 27–40. [Google Scholar] [CrossRef]
- Okabe, K.; Hayashi, M.; Yamawaki, Y.; Teranishi, M.; Honoki, K.; Mori, T.; Fukushima, N.; Tsujiuchi, T. Possible involvement of lysophosphatidic acid receptor-5 gene in the acquisition of growth advantage of rat tumor cells. Mol. Carcinog. 2011, 50, 635–642. [Google Scholar] [CrossRef] [PubMed]
- Oda, S.K.; Strauch, P.; Fujiwara, Y.; Al-Shami, A.; Oravecz, T.; Tigyi, G.; Pelanda, R.; Torres, R.M. Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunol. Res. 2013, 1, 245–255. [Google Scholar] [CrossRef] [PubMed]
- Yukiura, H.; Kano, K.; Kise, R.; Inoue, A.; Aoki, J. LPP3 localizes LPA6 signalling to non-contact sites in endothelial cells. J. Cell. Sci. 2015, 128, 3871–3877. [Google Scholar] [CrossRef] [PubMed]
- Palmer, S.M.; Snyder, L.; Todd, J.L.; Soule, B.; Christian, R.; Anstrom, K.; Luo, Y.; Gagnon, R.; Rosen, G. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest 2018, 154, 1061–1069. [Google Scholar] [CrossRef] [Green Version]
Receptor Name | Gα Protein Coupling | Human | Mouse | Aliases | References | ||||
---|---|---|---|---|---|---|---|---|---|
Gene Name | Chr Location | Pro Size (aa) | Gene Name | Chr Location | Pro Size (aa) | ||||
LPA1 | Gαi/o, Gαq/11, Gα12/13 | LPAR1 | 9q31.1 | 364 | Lpar1 | 4, 32.2 cM | 364 | EDG2, VZG1, Mrec1.3 | [23,34] |
LPA2 | Gαi/o, Gαq/11, Gα12/13 | LPAR2 | 19q12-13.11 | 351 | Lpar2 | 8, 33.91 cM | 348 | EDG4 | [23,24] |
LPA3 | Gαi/o, Gαq/11, Gα12/13 | LPAR3 | 1p22.3 | 353 | Lpar3 | 3, 71.03 cM | 354 | EDG7 | [13,24] |
LPA4 | Gαi/o, Gαq/11, Gα12/13, Gαs | LPAR4 | Xq21.1 | 370 | Lpar4 | X, 47.39 cM | 370 | P2Y9, GPR23 | [18,19] |
LPA5 | Gαi/o, Gαq/11, Gα12/13 | LPAR5 | 12q13.31 | 372 | Lpar5 | 6, 59.21 cM | 372 | GPR92, GPR93 | [23,24,42,43] |
LPA6 | Gαi/o, Gα12/13 | LPAR6 | 13q14.2 | 344 | Lpar6 | 14, 38.75 cM | 344 | P2Y5 | [23,24] |
© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yun, C.C. Lysophosphatidic Acid and Autotaxin-associated Effects on the Initiation and Progression of Colorectal Cancer. Cancers 2019, 11, 958. https://doi.org/10.3390/cancers11070958
Yun CC. Lysophosphatidic Acid and Autotaxin-associated Effects on the Initiation and Progression of Colorectal Cancer. Cancers. 2019; 11(7):958. https://doi.org/10.3390/cancers11070958
Chicago/Turabian StyleYun, C. Chris. 2019. "Lysophosphatidic Acid and Autotaxin-associated Effects on the Initiation and Progression of Colorectal Cancer" Cancers 11, no. 7: 958. https://doi.org/10.3390/cancers11070958